Marton Laurence

Director Marton Laurence buys 9,720 shares of RNXT; cluster buy pattern detected with 2 other insiders buying within 14 days

Marton Laurence (Director) purchased 9,720 shares of RenovoRx on 2026-03-20, bringing his holdings from 0 to 9,720 shares. This transaction is part of a cluster pattern—2 other insiders also bought within the past 14 days—suggesting potential coordinated activity among leadership. Notably, his prior two purchases at RNXT (on 2025-04-08 and 2024-01-26) both showed positive 90-day returns of 22.6% and 55.7% respectively, establishing a pattern of well-timed entry points at this specific ticker. Against this backdrop, the current stock price of $1.08 is 23.9% below the 52-week high, creating a circumstance where multiple insiders are initiating or adding positions in an unprofitable company with minimal recent revenue ($266.0K in the latest quarter and net loss of $-2.9M). The convergence of insider buying activity, favorable historical timing outcomes at this ticker, and depressed valuation relative to recent highs warrants investor attention to the underlying business developments driving this apparent confidence.

Director Marton Laurence buys 12,050 RNXT shares at $0.85; stock down 46.1% from 52-week high amid $-2.5M losses; 3 other insiders buying within 14 days

Marton Laurence, a director of unprofitable RenovoRx (net income $-2,471,000.00), purchased 12,050 shares at $0.85 on 2025-04-08, increasing his holding by 35.8% to 45,684 shares. The purchase occurs in a depressed price environment: the stock is currently $0.83, down 46.1% from its 52-week high of $1.54 and 8.8% lower than 30 days ago. Notably, three other insiders acquired shares within the same 14-day window, forming a cluster-buy pattern. While Laurence's prior buy at this ticker on 2024-01-26 achieved a 90-day return of +15.2%, the company remains deeply unprofitable and the stock's recent trajectory (down 37.1% over 90 days) contrasts sharply with his historical cross-ticker win rate of 100% at the 90-day mark.